Investigational drug · Phase 3
Maridebart cafraglutide
Also called: AMG 133
Not approved by FDA. In 14 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Obstructive Sleep Apnea.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
14
14 still active
All registered trials
30
Any phase or sponsor naming "Maridebart cafraglutide"
First trial start
2024
Nov 7, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
- Amgen14
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Maridebart cafraglutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Obstructive Sleep Apnea
- Diabetes Mellitus, Type 2
- Obesity or Overweight
- Heart Failure With Preserved Ejection Fraction
- Heart Failure With Mildly Reduced Ejection Fraction
- Overweight or Obesity and Elevated Liver Fat
- Atherosclerotic Cardiovascular Disease
- Obesity Disease
Approved drugs for the same conditions: Obesity and weight management · Heart failure · Cardiovascular and metabolic · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Maridebart cafraglutide" as an intervention, largest first.
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityPivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT07037433 · 12,800 participants (planned) · Start Jul 25, 2025 · Primary completion Jun 30, 2028
Drug: Maridebart Cafraglutide; Placebo · For: Atherosclerotic Cardiovascular Disease; Overweight; Obesity
Sites: Daphne, Alabama; Fairhope, Alabama; Huntsville, Alabama · 783 sites in all
- Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07037459 · 5,056 participants (planned) · Start Jun 25, 2025 · Primary completion Jun 30, 2028
Drug: Maridebart cafraglutide; Placebo · For: Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity
Sites: Birmingham, Alabama; Dothan, Alabama; Fairhope, Alabama · 686 sites in all
- Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightPivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT06858839 · 3,853 participants · Start Mar 12, 2025 · Primary completion Jan 21, 2027
Drug: Maridebart Cafraglutide; Placebo · For: Obesity
Sites: Anniston, Alabama; Daphne, Alabama; Mobile, Alabama · 243 sites in all
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07684235 · 3,200 participants (planned) · Start Jul 23, 2026 · Primary completion Dec 26, 2027
Drug: Maridebart cafraglutide; Placebo · For: Obesity; Overweight
Sites: Anniston, Alabama; Daphne, Alabama; Mobile, Alabama · 92 sites in all
- Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07866066 · 1,300 participants (planned) · Start Oct 16, 2026 · Primary completion Sep 6, 2028
Drug: Maridebart cafraglutide; Semaglutide · For: Diabetes Mellitus, Type 2
Sites: San Diego, California; Miami, Florida; Miami Lakes, Florida · 8 sites in all
- Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightPivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT06858878 · 1,105 participants · Start Mar 17, 2025 · Primary completion Jan 21, 2027
Drug: Maridebart cafraglutide; Placebo · For: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Sites: Mobile, Alabama; Gilbert, Arizona; Mesa, Arizona · 187 sites in all
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07684144 · 950 participants (planned) · Start Jul 29, 2026 · Primary completion Dec 26, 2027
Drug: Maridebart Cafraglutide; Placebo · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Gilbert, Arizona; Canoga Park, California; Cerritos, California · 45 sites in all
- Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT05669599 · 592 participants · Start Jan 18, 2023 · Primary completion Oct 8, 2024
Drug: Maridebart Cafraglutide; Placebo · For: Obesity; Overweight; Type 2 Diabetes Mellitus
Sites: Mobile, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 78 sites in all
- A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)Pivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT06660173 · 409 participants · Start Nov 7, 2024 · Primary completion Oct 6, 2025
Drug: Maridebart Cafraglutide; Placebo · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Birmingham, Alabama; Anaheim, California; Canoga Park, California · 96 sites in all
- Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple DosesPivotal-lookingNot yet recruiting
AmgenAmgen (AMGN)
NCT07921316 · 356 participants (planned) · Start Nov 9, 2026 · Primary completion Jul 26, 2027
Drug: Maridebart cafraglutide · For: Obesity; Overweight
Newest research
PubMed records naming it or its code names, newest first.
- Bidirectional pharmacology of GIP receptor targeting in obesity: Historical foundations, mechanistic divergence, and translational boundaries.
Liu C, Wang Y, Liu J, et al. · Peptides 2026
- The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms.
Davies I, Holst JJ, Rosenkilde MM, et al. · Annu Rev Nutr 2026
- Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.
Yie J, Mou Z, Liu X · Antib Ther 2026
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Lempesis IG, Dalamaga M · Metabol Open 2026
- Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists.
Paceana MA, Tartau LM, Boboc IKS, et al. · Pharmaceutics 2026
- Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity.
Wu B, Falsey JR, Netirojjanakul C, et al. · J Med Chem 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.